304.56

3.75% 11.66

After Hours: 304.57 0.010 +0.00%

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $304.56, with a volume of 2.87M. It is up +3.75% in the last 24 hours and up +15.44% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Previous Close:

$292.90

Open:

$292.45

24h Volume:

2.87M

Relative Volume:

2.92

Market Cap:

$39.71B

Revenue:

$2.35B

Net Income/Loss:

$-269.70M

P/E Ratio:

-145.72

EPS:

-2.09

Net Cash Flow:

$-75.39M

1W Performance:

+4.80%

1M Performance:

+15.44%

6M Performance:

+20.08%

1Y Performance:

+102.55%

1-Day Range:

$287.20

$306.00

1-Week Range:

$284.73

$306.00

52-Week Range:

$147.25

$306.00

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1178)

Industry

Biotechnology (671)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,230

Twitter

@alnylam

Next Earnings Date

2024-10-31

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	304.56	37.68B	2.35B	-269.70M	-75.39M	-2.09
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

03:12 AM

Alnylam stock soars to all-time high of $304.52 - Investing.com Australia

03:12 AM

May 29, 2025

Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha

May 29, 2025

May 28, 2025

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace

May 28, 2025

RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan

May 28, 2025

Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan

May 28, 2025

May 27, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch By Investing.com - Investing.com India

May 27, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch - Investing.com

May 27, 2025

Biogen partners with John Maraganore’s new RNAi startup - The Business Journals

May 27, 2025

May 26, 2025

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga

May 26, 2025

Alnylam supports LGBT community inside and outside the workplace - The Business Journals

May 26, 2025

May 24, 2025

Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus

May 20, 2025

May 19, 2025

Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN

May 19, 2025

Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus

May 19, 2025

May 18, 2025

Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus

May 18, 2025

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN

May 18, 2025

May 17, 2025

Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus

May 17, 2025

Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha

May 17, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire

May 17, 2025

May 16, 2025

High Growth US Tech Stocks To Watch In May 2025 - simplywall.st

May 16, 2025

May 15, 2025

Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

May 15, 2025

May 14, 2025

Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader

May 14, 2025

Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360

May 14, 2025

Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters

May 14, 2025

Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada

May 14, 2025

May 13, 2025